Reversible bilateral optic neuritis after Infliximab discontinuation in a patient with Crohn's disease

Journal of Crohn's and Colitis

Volumn 3, Issue 3, 2009, Pages 212-214

  Felekis, Taxiarchis ^a   Katsanos, Konstantinos ^a   Christodoulou, Dimitrios ^a   Asproudis, Ioannis ^a   Tsianos, Epameinondas V ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Crohn's disease; Inflammatory bowel disease; Infliximab; Multiple sclerosis; Optic neuritis; TNFa

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; INFLIXIMAB; MESALAZINE; METHYLPREDNISOLONE; OXYBUTYNIN; PREDNISOLONE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CROHN DISEASE; DISEASE ASSOCIATION; DRUG WITHDRAWAL; EYE EXAMINATION; HUMAN; HUMAN TISSUE; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PRIORITY JOURNAL; SACROILIITIS; URINE INCONTINENCE;

EID: 67651158821     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2009.04.001     Document Type: Article

References (17)

1. Buccino G.P., Corrente G., and Visintini D. Crohn's disease and multiple sclerosis: a single case report. Ital J Neurol Sci 15 (1994) 303-306
2. Purrmann J., Arendt G., and Cleveland S. Association of Crohn's disease and multiple sclerosis. Is there a common background?. J Clin Gastroenterol 14 (1992) 43-46
3. Behm B.W., and Bickston S.J. Tumor necrosis factor-alpha antibody for maintenance for remission in Crohn's disease (Review). Cochrane Collab 4 (2008)
4. Simsek I., Erdem H., Pay S., Sobaci G., and Dinc A. Optic neuritis occurring with anti-tumour necrosis factor α therapy. Ann Rheum Dis 66 (2007) 1255-1258
5. Strong B.Y., Erny B.C., Herzenberg H., and Razzeca K.J. Retrobulbar optic neuritis associated with infliximab in a patient with Crohn disease. Ann Intern Med 140 (2004) W34
6. Mejico L.J. Infliximab-associated retrobulbar optic neuritis. Arch Ophthalmol 122 (2004) 793-794
7. Sandborn W.J. Strategies for targeting tumour necrosis factor in IBD. Best Pract Res Clin Gastroenterol 17 (2003) 105-117
8. Robinson W.H., Genovese M.C., and Moreland L.W. Demyelinating and neurologic events reported in association with tumour necrosis α antagonism. Arthritis Rheum 44 (2001) 1977-1983
9. Magnano M.D., Robinson W.H., and Genovese M.C. Demyelination and inhibition of tumour necrosis factor (TNF). Clin Exp Rheumatol 22 Supple 35 (2004) 134-140
10. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomised, placebo-controlled multicenter study. Neurology 53 (1999) 457-465
11. Arnett H.A., Mason J., Marino M., Suzuki K., Matsushima G.K., and Ting J.P. TNFa promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 4 (2001) 1116-1122
12. Mikuls T.R., and Weaver A.L. Lessons learned in the use of tumor necrosis factor α inhibition in the treatment of rheumatoid arthritis. Curr Rheumatol Rep 5 (2003) 270-277
13. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor α neutralizing agent. N Engl J Med 345 (2001) 1098-1104
14. Felekis T., Katsanos K.H., Kitsanou M., et al. Spectrum and frequency of ophthalmologic manifestations in patients with inflammatory bowel disease; a prospective single center study. Inflamm Bowel Dis 15 (2009) 29-34
15. Constantinescu C.S., Whiteley A., and Blumhardt L.D. Long term azathioprine fails to prevent onset of multiple sclerosis: report of two cases. Mult Scler 6 (2000) 362-363
16. Andersen N.N., Caspersen S., Jess T., and Munkholm P. Occurrence of demyelinating diseases after anti-TNFa treatment of inflammatory bowel disease: a Danish Crohn Colitis Database study. J Crohn Colitis 2 (2008) 304-309
17. Fidder H., Schnitzler F., Ferrante M., et al. Long-term safety of Infliximab for the treatment of inflammatory bowel disease: a single center cohort study. Gut 58 (2009) 501-508